Abstract
Avascular necrosis (AVN) is one of the most frequent types of organ damage in systemic lupus erythematosus (SLE). However, little is currently known about the epidemiology of AVN in SLE patients. The aim of this study was to estimate the prevalence and incidence of AVN in Korean patients with SLE based on National Health Insurance (NHI) claims data and to determine the risk factors for AVN among SLE patients. This study was conducted using the 2006–2010 data of 25,358 SLE patients from the NHI program. AVN cases were defined as those with at least one diagnosis of AVN. The prevalence was calculated by dividing the number of AVN cases by the number of SLE cases in the same year. The annual incidence was calculated by dividing the number of incident AVN cases by the number of SLE-prevalent cases not previously diagnosed with AVN. Patients who developed AVN in 2008–2010 were compared with SLE patients who did not develop AVN to identify any risk factors. The prevalence of AVN among SLE patients (2006–2010) was 31.5–34.2 per 1,000 persons and was similar in all the years studied. The incidence per 1,000 persons of AVN among SLE patients was 8.6 [95 % confidence interval (95 % CI) 6.9–10.3] in 2008, 9.8 (95 % CI 8.0–11.6) in 2009, and 8.4 (95 % CI 6.8–10.0) in 2010. Regression analysis indicated that taking an oral corticosteroid [odds ratio (OR) 2.12, 95 % CI 1.39–3.23] or an intravenous corticosteroid (OR 1.5, 95 % CI 1.2–1.89) was significantly associated with AVN. In addition, AVN was associated with use of immunosuppressive agents (OR 2.12, 95 % CI 1.66–2.72), hydroxychloroquine (OR 1.4, 95 % CI 1.09–1.81), and lipid-lowering agents (OR 1.78, 95 % CI 1.24–2.57) among the prescribed medications, and with hypertension (OR 1.39, 95 % CI 1.08–1.79) among the comorbidities. The prevalence and incidence of AVN among SLE patients, which were 31.5–34.2 and 8.4–9.8 per 1,000 persons, respectively, may be representative of the entire population of symptomatic AVN patients with SLE in Korea. AVN is associated with the use of corticosteroids, immunosuppressants, hydroxychloroquine, lipid-lowering agents, and with hypertension. Studies of large, prospective cohorts are needed to confirm these results.
Similar content being viewed by others
References
Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59(6):462–467
Uea-areewongsa P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P (2009) Factors associated with osteonecrosis in Thai lupus patients: a case control study. J Clin Rheumatol 15(7):345–349. doi:10.1097/RHU.0b013e3181ba3423
Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, Onat AM, Avan R, Cetin GY, Gul A, Ocal L, Aral O (2012) Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 32(1):177–182. doi:10.1007/s00296-010-1597-9
Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y (2010) Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 468(10):2715–2724. doi:10.1007/s11999-010-1292-x
Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32(2):94–124
Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Orheumatol 28(4):761–765
Kunyakham W, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2012) Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Paci J Allergy Immunol 30(2):152–157
Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900
Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24(4):654–662
Migliaresi S, Picillo U, Ambrosone L, Di Palma G, Mallozzi M, Tesone ER, Tirri G (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3(1):37–41
Cho SK, Sung YK, Choi CB, Bae SC (2012) Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int 32(12):3851–3856. doi:10.1007/s00296-011-2312-1
Kim JY, Kim HJ, Jung SY, Kim KI, Song HJ, Lee JY, Seong JM, Park BJ (2012) Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database. BMC Cardiovasc Disord 12:60. doi:10.1186/1471-2261-12-60
Sung YK, Cho SK, Choi CB, Bae SC (2013) Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int 33(6):1525–1532. doi:10.1007/s00296-012-2590-2
Shim JS, Sung YK, Joo YB, Lee HS, Bae SC (2013) Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol Int. doi:10.1007/s00296-013-2915-9
Kang JS, Park S, Song JH, Jung YY, Cho MR, Rhyu KH (2009) Prevalence of osteonecrosis of the femoral head: a nationwide epidemiologic analysis in Korea. J Arthroplasty 24(8):1178–1183. doi:10.1016/j.arth.2009.05.022
Yamaguchi R, Yamamoto T, Motomura G, Ikemura S, Iwamoto Y (2011) Incidence of nontraumatic osteonecrosis of the femoral head in the Japanese population. Arthritis Rheum 63(10):3169–3173. doi:10.1002/art.30484
Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K (2010) Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 62(2):609–615. doi:10.1002/art.27236
Asherson RA, Liote F, Page B, Meyer O, Buchanan N, Khamashta MA, Jungers P, Hughes GR (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20(2):284–288
Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, Moriya H (2001) Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60(12):1145–1148
Sung YK, Hur NW, Sinskey JL, Park D, Bae SC (2007) Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 34(5):987–991
Fialho SC, Bonfa E, Vitule LF, D’Amico E, Caparbo V, Gualandro S, Pereira RM (2007) Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16(4):239–244. doi:10.1177/0961203307076771
Nagasawa K, Ishii Y, Mayumi T, Tada Y, Ueda A, Yamauchi Y, Kusaba T, Niho Y (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48(8):672–676
Calvo-Alen J, McGwin G, Toloza S, Fernandez M, Roseman JM, Bastian HM, Cepeda EJ, Gonzalez EB, Baethge BA, Fessler BJ, Vila LM, Reveille JD, Alarcon GS (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study. Ann Rheum Dis 65(6):785–790. doi:10.1136/ard.2005.040428
Nagasawa K, Tada Y, Koarada S, Horiuchi T, Tsukamoto H, Murai K, Ueda A, Yoshizawa S, Ohta A (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14(5):385–390
Aranow C, Zelicof S, Leslie D, Solomon S, Barland P, Norman A, Klein R, Weinstein A (1997) Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 24(12):2318–2322
Kim HA, Song YW (1996) Avascular Necrosis in a corticosteroid-treated rheumatic disease population. J Korean Rheum Assoc 3:110–117
Prasad R, Ibanez D, Gladman D, Urowitz M (2007) The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case–control study of inception patients. Lupus 16(3):157–162
Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP (2002) Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 74(8):1147–1152. doi:10.1097/01.tp.0000035848.73883.1b
Yang P, Liu YF, Yang L, Wei Q, Zeng H (2010) Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clin Cardiol 33(6):E81–E86. doi:10.1002/clc.20719
Caramaschi P, Biasi D, Dal Forno I, Adami S (2012) Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication. Autoimmune Dis 2012:725249. doi:10.1155/2012/725249
Acknowledgments
This study was supported in part by grants from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Nos. A080588 and A102065).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Joo, Y.B., Sung, YK., Shim, JS. et al. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study. Rheumatol Int 35, 879–886 (2015). https://doi.org/10.1007/s00296-014-3147-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-3147-3